Alembic Pharmaceuticals: Should You Buy, Hold, or Sell Right Now?

Alembic Pharmaceuticals share price has pulled back from its 52-week high of Rs 998, and the Alembic Pharmaceuticals share price now trades near Rs 838 on the NSE, though it remains well above its 52-week low of Rs 635.80. That leaves investors weighing whether this generics-focused pharma company is a buy at current levels, a hold for existing shareholders, or a stock to trim given near-term margin pressure from US business investments.

This Alembic Pharma stock analysis covers the latest Q1 FY27 results, valuation against the pharmaceutical sector, shareholding pattern and the technical setup, before laying out the Alembic Pharma buy or sell case using figures sourced from exchange filings and public disclosures.

Click Here – Get Free Investment Predictions

About Alembic Pharmaceuticals

Keep this backdrop in mind when reading the rest of this Alembic Pharmaceuticals share price review. That context matters when weighing Alembic Pharmaceuticals share price against peers. Before deciding on Alembic Pharmaceuticals share price, it helps to understand the underlying business. Alembic Pharmaceuticals Ltd. is a Vadodara-based, India-headquartered pharmaceutical company with a diversified business spanning India branded formulations, US generics, international formulations outside the US, and active pharmaceutical ingredients (API). The company has built a substantial US generics presence, backed by 245 total USFDA approvals as of recent disclosures.

Alembic Pharma's management has flagged that ongoing investments in its US branded specialty business are weighing on near-term margins, though the company expects this drag to reduce as sales in that specialty segment continue to ramp up over coming quarters, alongside continued exclusivity benefits on select products like Bosutinib.

Alembic Pharmaceuticals Share Price Today: Key Levels

The table below summarises where Alembic Pharma share price stands right now against its recent trading range and market value.

Metric	Value
Alembic Pharmaceuticals CMP (NSE)	Rs 838.00
Alembic Pharmaceuticals CMP (BSE)	Rs 837.55
Day's Change	+0.37% (Rs +3.10)
52-Week High	Rs 998.00
52-Week Low	Rs 635.80
Market Capitalisation	Approximately Rs 16,430 crore
NSE Volume (latest session)	90,627 shares

Alembic Pharma share price is trading in the middle of its 52-week range, reflecting a business balancing strong revenue growth against near-term margin investment in its US branded specialty segment.

Check the Univest Screener for Live Stock Data

Alembic Pharmaceuticals Financial Performance

Track this line item closely if you are following Alembic Pharmaceuticals share price closely. These results are the single biggest driver of Alembic Pharmaceuticals share price in the near term. The Alembic Pharmaceuticals share price trend is closely tied to how these numbers evolve each quarter. Alembic Pharmaceuticals reported Q1 FY27 net sales growth of 25.66 percent year on year to Rs 2,149.77 crore, driven substantially by strong US generic launches and continued exclusivity benefits, though consolidated net profit of Rs 173.07 crore represented a sequential decline of 14.62 percent from Q4 FY26 even as it improved 12.11 percent year on year.

Management has raised its FY27 US growth outlook following the strong Q1 performance, citing Bosutinib exclusivity continuing until November as a near-term tailwind for Q2 US sales, while acknowledging that ongoing investments in the US branded specialty business continue to weigh on overall margins in the near term.

Period	Revenue	Net Profit	Comment
Q1 FY27 (Jun 2026)	Rs 2,149.77 crore	Rs 173.07 crore	+25.66% revenue, +12.11% profit YoY

Valuation Check: Is Alembic Pharmaceuticals Share Price Expensive?

It is one of the clearest signals available on Alembic Pharmaceuticals share price today. Investors comparing Alembic Pharmaceuticals share price with peers usually start here. Any view on Alembic Pharmaceuticals share price should start from these valuation multiples. Alembic Pharma share price currently reflects a price to earnings ratio of about 24 times trailing earnings, a discount to the broader pharmaceutical sector average of roughly 38 times. The price to book ratio stands near 2.9 times, with return on equity at 11.89 percent, a reasonable though not exceptional figure for a generics-focused pharma company.

Debt to equity of 0.25 is modest, and the stock offers a dividend yield of 1.44 percent. Historically, pharmaceutical companies with strong US generics pipelines and rising branded specialty exposure have re-rated toward sector-average multiples once new segment investments begin showing improved returns, so the current discount is a useful benchmark to track against future margin trends.

Technical Signals: What the Chart Shows

Price action here often foreshadows the next move in Alembic Pharmaceuticals share price. Alembic Pharma share price is currently positioned about 16 percent below its 52-week high of Rs 998 and roughly 32 percent above its 52-week low of Rs 635.80, placing it in the middle of its annual trading range. A stock trading near the midpoint of its range, following a quarter of strong revenue growth but a sequential profit dip, often reflects the market weighing near-term margin investment against longer-term US business potential.

Trading volumes remain moderate, so investors should track Alembic Pharma share price over several sessions, particularly around upcoming Q2 results where the Bosutinib exclusivity benefit is expected to be a factor, rather than reacting to any single day's move at these technical levels.

Download the Univest iOS App or Univest Android App to track Alembic Pharma's live price and technical levels.

Shareholding Pattern

This is a useful lens for reading Alembic Pharmaceuticals share price over time. Shifts here can influence Alembic Pharmaceuticals share price more than headline news on some sessions. Promoter shareholding in Alembic Pharmaceuticals stands at approximately 69.9 percent as of the latest available data, with foreign institutional investors holding around 4.2 percent, domestic institutions around 7.2 percent, and public shareholders holding roughly 10 percent of the equity.

This high promoter concentration reflects the long-standing family ownership structure typical of many established Indian pharmaceutical companies.

Why Investors Are Watching Alembic Pharmaceuticals

• Strong US generics growth: Q1 FY27 revenue grew 25.66 percent year on year, driven by robust US generic launches and continued exclusivity benefits on select products.
• Valuation discount to sector: A 24x PE against a 38x sector average leaves room for re-rating as the US branded specialty investment cycle matures.
• Raised FY27 US growth outlook: Management has raised its FY27 US growth guidance following the strong Q1 print, citing continuing Bosutinib exclusivity into Q2.
• Extensive USFDA approval base: 245 total USFDA approvals give Alembic Pharma a broad platform for continued US generic product launches.

Risks and Factors to Watch

• Near-term margin pressure: Investments in the US branded specialty business are weighing on overall margins, with profit declining 14.62 percent sequentially in Q1 FY27 despite strong revenue growth.
• Dependence on exclusivity windows: Part of the near-term US growth outlook is tied to time-limited exclusivity on products like Bosutinib, which will eventually face increased competition.
• Sector-wide pricing pressure: Like all generics-focused pharma companies, Alembic Pharma faces periodic US pricing pressure and competitive intensity in its generics portfolio.
• High promoter concentration: With promoters holding around 69.9 percent, the free float is relatively limited, which can affect stock liquidity.

Alembic Pharmaceuticals Share Price Target: What the Data Suggests

That is a key gap in the public data on Alembic Pharmaceuticals share price today. Until then, Alembic Pharmaceuticals share price remains best tracked through live, verified data rather than a single fixed number. Alembic Pharma does not have a single widely published, current analyst consensus 12-month share price target consistently available at this time. What the data shows is a company with strong revenue momentum trading at a discount to its sector, while working through a margin investment cycle in its US branded specialty business.

Historically, pharmaceutical companies have re-rated once new segment investments begin contributing positively to margins rather than diluting them. Investors who want live, updated target price research can check the Univest Screener, and should consult a SEBI-registered investment adviser for guidance tailored to their own goals.

Alembic Pharmaceuticals: Should You Buy, Hold, or Sell Right Now?

This is the core question behind Alembic Pharmaceuticals share price right now. The Alembic Pharma buy or sell decision depends on how you weigh strong revenue growth against near-term margin pressure from the US business investment cycle.

The case for buying: Investors who believe in Alembic Pharma's US generics growth trajectory and are comfortable with near-term margin investment may see the stock's discount to sector PE, combined with raised FY27 US guidance, as an attractive entry point.

The case for holding: Existing shareholders who already track the company's US branded specialty ramp-up may prefer to stay invested and watch for margin improvement as investments mature over coming quarters.

The case for trimming or waiting: Investors who prefer to see the US branded investment cycle actually turn margin-accretive, or who are cautious about the sequential profit decline in Q1 FY27, may prefer to wait for clearer evidence before adding fresh exposure.

Historically, well-executed pharma growth investments have paid off over a multi-year horizon, but near-term margin dilution can persist longer than expected, so weigh this against your own investment horizon and consult a SEBI-registered investment adviser if unsure.

Conclusion

Alembic Pharma share price reflects a pharmaceutical company delivering strong US-led revenue growth while investing in its branded specialty business, trading at a discount to the broader pharma sector on PE despite that near-term margin pressure. Whether that combination makes the stock a buy, a hold or a candidate to trim depends on your confidence in the US branded business investment paying off over time. This article is for informational purposes and not a personalised investment recommendation.

Q1. Is Alembic Pharmaceuticals a good stock to buy right now?

Ans. Alembic Pharma delivered 25.66 percent revenue growth in Q1 FY27 and trades at a discount to the pharma sector on PE, which appeals to value-focused investors. However, near-term margins are being weighed down by US branded specialty investments, so growth in profit has lagged revenue growth recently.

Q2. What is the Alembic Pharmaceuticals share price today?

Ans. Alembic Pharmaceuticals share price is trading around Rs 838 on the NSE, up about 0.37 percent on the day. The stock's 52-week high is Rs 998 and its 52-week low is Rs 635.80.

Q3. What is the Alembic Pharmaceuticals share price target?

Ans. Alembic Pharma does not have a single widely published, current analyst consensus 12-month share price target consistently available at this time. Investors can check live research on the Univest Screener and consult a SEBI-registered adviser for a personalised view.

Q4. Why did Alembic Pharma profit decline sequentially in Q1 FY27?

Ans. Alembic Pharma's Q1 FY27 net profit fell 14.62 percent sequentially from Q4 FY26, even as it rose 12.11 percent year on year, mainly due to ongoing investments in the company's US branded specialty business weighing on margins.

Q5. What is Alembic Pharmaceuticals' market capitalisation and PE ratio?

Ans. Alembic Pharmaceuticals has a market capitalisation of approximately Rs 16,430 crore and trades at a price to earnings ratio of about 24 times, a discount to the pharmaceutical sector average PE of roughly 38 times.

Q6. What is the shareholding pattern of Alembic Pharmaceuticals?

Ans. Promoter shareholding in Alembic Pharmaceuticals stands at approximately 69.9 percent, with foreign institutions holding around 4.2 percent, domestic institutions around 7.2 percent, and public shareholders holding roughly 10 percent.